1. Introduction

   • K. Andrassy
   • W. Marget

   EditorialNotes Pages: S240 - S240

2. General remarks on cephalosporins and semisynthetic penicillins — aspects of clinical administration

   • W. Marget

   OriginalPaper Pages: S241 - S243

3. Pharmacological properties of cephalosporins

   • W. Christ

   OriginalPaper Pages: S244 - S252

4. The meaning of the development of flomoxef and clinical experience in Japan

   • M. Ito
   • T. Ishigami

   OriginalPaper Pages: S253 - S257

5. Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef

   • H. Grimm

   OriginalPaper Pages: S258 - S263

6. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE 2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin)

   • A. Bauernfeind
   • S. Schweighart
   • R. Jungwirth

   OriginalPaper Pages: S264 - S275

7. In vitro activity of flomoxef and cefazolin in combination with vancomycin

   • C. Simon
   • Maria Simon

   OriginalPaper Pages: S276 - S278

8. The in vitro activity of flomoxef compared to four other cephalosporins and imipenem

   • P. M. Shah
   • H. Knothe

   OriginalPaper Pages: S279 - S283

9. Effect of flomoxef on blood coagulation and alcohol metabolism

   • K. Uchida
   • T. Matsubara

   OriginalPaper Pages: S284 - S295

10. Pharmacokinetics and hemostasis following administration of a new, injectable oxacephem (6315-S, flomoxef) in volunteers and in patients with renal insufficiency

    • K. Andrassy
    • J. Koderisch
    • K. Hirauchi

    OriginalPaper Pages: S296 - S302